butyric acid isopropylidenehydrazide | 95903-98-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: butyric acid isopropylidenehydrazide
• 英文别名: Isopropyliden-butyryl-hydrazin；Buttersaeure-isopropylidenhydrazid；N-(propan-2-ylideneamino)butanamide
• CAS: 95903-98-3
• 化学式: C₇H₁₄N₂O
• 分子量: 142.201
• InChiKey: XEQRAGBXXUBCEM-UHFFFAOYSA-N

物化性质

• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  butyric acid isopropylidenehydrazide 在 四氢呋喃 、 lithium aluminium tetrahydride 作用下， 生成 N-butyl-N'-isopropyl-hydrazine
  参考文献：
  名称：

  The Synthesis of Alkylhydrazines. II. The Reduction of 1-Acyl-2-alkylidenehydrazines with Lithium Aluminum Hydride

  摘要：

  DOI：

  10.1021/ja01559a048
• 作为产物：
  描述：

  丙酮 、 丁酰肼 生成 butyric acid isopropylidenehydrazide
  参考文献：
  名称：

  Stolle; Zinsser, Journal fur praktische Chemie (Leipzig 1954), 1904, vol. <2> 69, p. 491

  摘要：

  DOI：

文献信息

• [EN] TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)<br/>[FR] MOLÉCULES DE RECRUTEMENT D'ANTICORPS CONJUGUÉS À UN AGONISTE DE TLR)
  申请人：UNIV YALE

  公开号：WO2013166110A1

  公开（公告）日：2013-11-07

  The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

  本发明涉及嵌合化学化合物，用于招募抗体到癌细胞，特别是前列腺癌细胞或转移的前列腺癌细胞。根据本发明的化合物包括一个与细胞结合末端（CBT）和通过连接物和多功能连接组或分子共价结合的抗体结合末端（ABT）基团和Toll样受体激动剂（TLR）。
• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2017184999A1

  公开（公告）日：2017-10-26

  The present disclosure provides compounds of any one of Formulae (I), (II), and (III). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZHl) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了任一式(I)、(II)和(III)中的化合物。本文描述的这些化合物是组蛋白甲基转移酶（例如，增强子of zeste同源物1（EZHl）和增强子of zeste同源物2（EZH2））的抑制剂，并可用于治疗和/或预防广泛范围的疾病（例如，增殖性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。
• Bouveault; Bongert, Bulletin de la Societe Chimique de France, 1902, vol. <3> 27, p. 1044,1049
  作者：Bouveault、Bongert

  DOI：——

  日期：——
• [EN] AQUEOUS POLYMER COMPOSITION<br/>[FR] COMPOSITION AQUEUSE DE POLYMÈRE
  申请人：COMMW SCIENT IND RES ORG

  公开号：WO2018112555A1

  公开（公告）日：2018-06-28

  The present invention relates to a storage stable crosslinkable aqueous polymer composition comprising: (a) an aqueous liquid; (b) a copolymer solubilised in the aqueous liquid by a fugitive non-gas acid, the copolymer comprising polymerised residues of: (i) ethylenically unsaturated monomer comprising a basic functional group that is protonated by the fugitive non-gas acid, the polymerised residues of that monomer being present in an amount of less than 25 mol%, relative to the total number of mols of polymerised monomer residues of the copolymer; (ii) ethylenically unsaturated monomer comprising a functional group for promoting crosslinking of the copolymer; and (iii) hydrophobic ethylenically unsaturated monomer; and (c) (i) a reversibly blocked crosslinking agent for promoting crosslinking of the copolymer, and (ii) a fugitive crosslinking inhibitor for inhibiting crosslinking of the copolymer by the reversibly blocked crosslinking agent.
• Stolle; Zinsser, Journal fur praktische Chemie (Leipzig 1954), 1904, vol. <2> 69, p. 491
  作者：Stolle、Zinsser

  DOI：——

  日期：——